The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. After-hours trades for Keros Therapeutics Inc. (KROS) shows that investor sentiment remained same, with the stock’s consolidated last price remained same to $44.27. The Keros Therapeutics Inc. has recorded 139 volume in the after hours trading session. Most recently, Yahoo Finance reported about the stock as it publicized that Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Keros Therapeutics Inc. is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. At the end of the last regular session, the stock closed at $44.27 and fluctuated between $48.24 as its day high and $42.29 as its day low. The current market capitalization of Keros Therapeutics Inc. is $1.38B. A total of 0.74 million shares were traded on the day, compared to an average of 221.17K shares.
Additionally, investors take into account insider trades when predicting how a stock will perform. During the recent three months, KROS has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 9 BUYs and 27 SELLs from insiders. Insiders purchased 83,492 shares during that period but sold 90,620.
In the most recent transaction, Lachey Jennifer sold 46,034 shares of KROS for 30.00 per share on Jul 15. After the transaction, the Chief Scientific Officer now owns 95,100 company shares. In a previous transaction on Jul 13, Lachey Jennifer sold 1,916 shares at 30.00 per share. KROS shares that Chief Scientific Officer owns now total 95,100.
Among the insiders who sold shares, Lachey Jennifer disposed of 5,300 shares on May 11 at a per-share price of $41.90. This resulted in the Chief Scientific Officer holding 85,700 shares of KROS after the transaction. In another insider transaction, Lachey Jennifer sold 5,300 shares at $62.77 per share on Apr 11. Company shares held by the Chief Scientific Officer now total 85,700.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. According to analysts who have offered 12-month price targets for KROS in the last 3 months, the mean price target is $96.67 with high estimates of $120.00 and low estimates of $75.00. In terms of 52-week highs and lows, KROS has a high of $68.29 and a low of $24.38.
As of this writing, KROS has an earnings estimate of -$1.11 per share for the current quarter. EPS was calculated based on a consensus of 6 estimates, with a high estimate of -$0.99 per share and a lower estimate of -$1.18. The company reported an EPS of -$1.13 in the last quarter, which was -6.60% lower than expectations of -$1.06.
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information.
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 7 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for KROS is Overweight with a score of 5.00. A total of 7 analysts rated the stock as Buy while 0 rated it as Overweight while 0 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.